Inactivated, live-attenuated, recombinant, and adjuvanted vaccines
This page catalogs 20 influenza vaccine products spanning seasonal, pandemic, and stockpile formulations. Influenza vaccines represent the broadest range of manufacturing platforms for any single disease — including egg-based, cell-based, recombinant, adjuvanted, live-attenuated intranasal, and pandemic-specific products.
Last updated: April 2026.
| Trade Name | Generic Designation | Manufacturer | Vaccine Type | Regulatory Status & Year | Key Notes |
|---|---|---|---|---|---|
| Fluzone / Fluzone HD | Influenza virus vaccine (inactivated) | Sanofi Pasteur | Inactivated (egg-based) | FDA Licensed | Standard and high-dose formulations |
| FluMist | Influenza vaccine, live intranasal | MedImmune/AstraZeneca | Live-attenuated (intranasal) | FDA Licensed, 2003 | Nasal spray; trivalent and quadrivalent |
| Fluad / Fluad Quadrivalent | Influenza vaccine, adjuvanted | Seqirus (CSL) | Inactivated + MF59 adjuvant | FDA Licensed, 2015 | MF59-adjuvanted for ages 65 and older |
| Flucelvax Quadrivalent | Influenza vaccine (cell culture) | Seqirus (CSL) | Inactivated (cell-based) | FDA Licensed, 2012 | Cell-culture based; egg-free |
| Flublok / Flublok Quadrivalent | Influenza vaccine (recombinant) | Sanofi Pasteur | Recombinant HA protein | FDA Licensed, 2013 | Recombinant; egg-free; ages 18+ |
| Afluria / Afluria Quadrivalent | Influenza vaccine | Seqirus (CSL) | Inactivated (egg-based) | FDA Licensed | Standard quadrivalent formulation |
| Fluvirin / Fluvirin Quadrivalent | Influenza vaccine | Seqirus (CSL) | Inactivated (egg-based) | FDA Licensed | Ages 4+ formulation |
| Fluarix / Fluarix Quadrivalent | Influenza vaccine | GSK | Inactivated (egg-based) | FDA Licensed | Ages 6 months+ formulation |
| FluLaval / FluLaval Quadrivalent | Influenza vaccine | GSK | Inactivated (egg-based) | FDA Licensed | Ages 6 months+ formulation |
| Agriflu | Influenza vaccine | Seqirus (CSL) | Inactivated (egg-based) | FDA Licensed | Ages 18+ formulation |
| Fluzone Intradermal | Influenza vaccine (intradermal) | Sanofi Pasteur | Inactivated (egg-based, intradermal) | FDA Licensed; Discontinued | Intradermal delivery; discontinued |
| Audenz | A/H5N1 influenza vaccine, adjuvanted | Seqirus (CSL) | Inactivated + MF59 adjuvant (pandemic) | FDA Licensed, 2015 | Pandemic H5N1 stockpile vaccine |
| Fluad Pediatric | Influenza vaccine, adjuvanted (pediatric) | Seqirus (CSL) | Inactivated + MF59 adjuvant | FDA Licensed, 2022 | Pediatric MF59-adjuvanted formulation |
| Influvac | Influenza vaccine | Viatris (Mylan) | Inactivated (egg-based) | EMA Authorized | European formulation |
| Vaxigrip / VaxigripTetra | Influenza vaccine | Sanofi Pasteur | Inactivated (egg-based) | EMA Authorized | European and international formulation |
| Alfana | Influenza vaccine (cell-based) | Seqirus (CSL) | Inactivated (cell-based) | EMA Authorized | European cell-culture formulation |
| OptaFlu | Influenza vaccine (cell-based) | Novartis/Sequirus | Inactivated (cell-based) | EMA Authorized; Discontinued | European cell-based; discontinued |
| Supemtek | Influenza vaccine (recombinant) | Sanofi Pasteur | Recombinant HA protein | FDA Licensed, 2020 | Recombinant; egg-free; ages 18+ |
| Arexvy (RSV+Influenza) | RSV + Influenza combination | GSK | Combination (adjuvanted) | FDA Licensed, 2025 | First approved RSV-flu combination |
Regulatory data sourced from FDA CBER Vaccines Licensed for Use in the United States (March 2026) and EMA Medicines database. Catalog scope informed by Khan, Shaz, The Ultimate Vaccine Timeline.